Cumberland Pharmaceuticals CPIX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $41.94M+2.1% | $44.52M+17.6% | $41.28M+12.2% | $42.07M+11.3% | $41.08M+5.8% | ||
| $7.18M+11.5% | $6.67M+1.2% | $6.4M+4.3% | $6.74M+2.3% | $6.44M+0.7% | ||
| $34.76M+0.3% | $37.85M+21.0% | $34.88M+13.8% | $35.34M+13.2% | $34.65M+6.8% | ||
| 82.9%-1.4pp | 85%+2.4pp | 84.5%+1.2pp | 84%+1.4pp | 84.3%+0.8pp | ||
| $5.73M+15.7% | $5.57M+15.6% | $5.31M+10.9% | $5.36M-0.8% | $4.95M-9.8% | ||
| $19.93M+16.6% | $19.1M+12.2% | $17.11M-2.5% | $17.08M-4.6% | $17.1M-6.7% | ||
| $12.04M+7.3% | $11.95M+7.4% | $11.24M0.0% | $11.34M+4.0% | $11.22M+6.7% | ||
| $4.28M-7.9% | $4.03M-15.0% | $4.48M-42.8% | $4.55M-42.6% | $4.64M-41.8% | ||
| $49.15M+10.8% | $47.31M+6.8% | $44.54M-6.3% | $45.06M-7.5% | $44.35M-9.0% | ||
| -$7.21M-121% | -$2.79M+56.6% | -$3.26M+69.7% | -$2.99M+72.7% | -$3.27M+66.9% | ||
| -17.2%-9.2pp | -6.3%+10.7pp | -7.9%+21.4pp | -7.1%+21.8pp | -8%+17.5pp | ||
| $418.03K-35.8% | $495.99K-18.1% | $606.31K+8.1% | $633.98K+18.8% | $650.78K+8.5% | ||
| $429.07K+18.1% | $476.75K+42.5% | $491.45K+59.2% | $429.06K+26.9% | $363.41K+9.0% | ||
| —— | —— | —— | —— | $0— | ||
| -$7.2M-117% | -$2.81M+56.5% | -$3.38M+68.7% | -$2.96M+71.3% | -$3.32M+60.2% | ||
| $38.46K+235% | $40.26K+278% | -$39.99K-167% | -$34.21K-162% | -$28.44K-157% | ||
| -$7.38M-125% | -$2.84M+56.2% | -$3.33M+69.4% | -$2.93M+71.7% | -$3.28M+61.1% | ||
| -17.6%-9.6pp | -6.4%+10.7pp | -8.1%+21.5pp | -7%+20.5pp | -8%+13.7pp | ||
| -$0.49-96.0% | -$0.19+59.6% | -$0.24+68.8% | -$0.22+69.9% | -$0.25+57.6% | ||
| -$0.49-96.0% | -$0.19+59.6% | -$0.24+68.8% | -$0.22+69.9% | -$0.25+57.6% | ||
| 59.7M+3.9% | 60M+6.6% | 59.2M+4.7% | 58.3M+2.7% | 57.5M+0.5% | ||
| 59.7M+4.5% | 59.7M+6.0% | 58.9M+4.2% | 58M+2.2% | 57.2M+0.2% | ||
| $4.28M-7.9% | $4.03M-15.0% | $4.48M-42.8% | $4.55M-42.6% | $4.64M-41.8% | ||
| $41.94M+2.1% | $44.52M+17.6% | $41.28M+12.2% | $42.07M+11.3% | $41.08M+5.8% | ||
| -$7.21M-121% | -$2.79M+56.6% | -$3.26M+69.7% | -$2.99M+72.7% | -$3.27M+66.9% | ||
| -$2.82M-287% | $1.35M+188% | $1.34M+122% | $1.69M+127% | $1.51M+130% | ||
| -$2.82M-287% | $1.35M+188% | $1.34M+122% | $1.69M+127% | $1.51M+130% | ||
| -6.7%-10.4pp | 3%+7.1pp | 3.2%+19.9pp | 4%+20.3pp | 3.7%+16.7pp | ||
| -$7.21M-121% | -$2.79M+56.6% | -$3.26M+69.7% | -$2.99M+72.7% | -$3.27M+66.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cumberland Pharmaceuticals's revenue?
- Cumberland Pharmaceuticals (CPIX) generated $41.9M in revenue over the trailing twelve months, up 2.1% year over year.
- Is Cumberland Pharmaceuticals profitable?
- Cumberland Pharmaceuticals is not currently profitable: it reported a net loss of $7.4M over the trailing twelve months, a -17.6% net margin.
- What are Cumberland Pharmaceuticals's profit margins?
- Gross margin is 82.9% and operating margin is -17.2%, with a -17.6% net margin.
- What is Cumberland Pharmaceuticals's earnings per share?
- Cumberland Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.49.
- Where does Cumberland Pharmaceuticals's income statement data come from?
- Every line is extracted from Cumberland Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
